The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

Shares of drugmaker Catalyst Pharmaceuticals (NASDAQ: CPRX) are up a little more than 8% as of midday on Thursday, down slightly from an intraday peak gain of nearly 13%. The company's fourth-quarter ...

Catalyst Pharmaceuticals' Firdapse delivers strong growth with a 37% CAGR. Click here to find out why CPRX stock is a Hold.

Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven ...

Total Revenues of $491.7 Million, Marking Another Year of Record GrowthFull Year 2024 Total Revenues Grew 23.5% YoY, Driven by ...

Handelsbanken Fonder AB grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 2.9% in the 4th ...

Stephens analyst Sudan Loganathan raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $40 from $33 and keeps an Overweight ...

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living ...

Catalyst Pharmaceuticals reported 2024 revenues of $491.7 million, projecting growth to $545-$565 million in 2025. Catalyst Pharmaceuticals, Inc. reported a record total revenue of $491.7 million ...

Ieq Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) during the 4th quarter, HoldingsChannel reports. The firm purchased 15,013 shares of ...

Full Year 2024 Results Key Financial Results Revenue: US$491.7m (up 24% ...